BERKELEY, CA, and CORALVILLE, IA – February 23, 2016
– Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, and Integrated DNA Technologies, Inc. (IDT), a producer of custom synthetic oligonucleotide-based technologies for genomics applications, have entered into a non-exclusive license agreement under which Caribou has granted IDT worldwide rights to commercialize CRISPR-Cas9 reagents under Caribou’s intellectual property. The license is subject to a research use limited label.
“We are proud to partner with Integrated DNA Technologies, a prominent leader in the field of nucleic acid–based technologies,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “This partnership will help provide researchers with the tools they need to conduct effective CRISPR-Cas9 research.”
Joseph Walder, M.D., Ph.D., President and Chief Executive Officer of IDT, said, “IDT is excited to be the first genomics company to have reached this agreement with Caribou, a recognized leader in the field of CRISPR-Cas9 research. This license allows us to deliver the entire spectrum of products for CRISPR-Cas9 genome editing, solidifying our position at the forefront of this groundbreaking technology.”
IDT’s CRISPR-Cas9 reagents will be used by customers conducting biological research across a broad range of scientific areas such as drug discovery, plant biology, and genomics. IDT’s CRISPR-Cas9 reagents will provide researchers with the ability to edit genomic DNA precisely and efficiently.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. is a developer of technology-based solutions for cellular engineering and analysis based on CRISPR systems. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com
and follow @CaribouBio
. “Caribou Biosciences” and the Caribou logo are trademarks of Caribou Biosciences, Inc.
Integrated DNA Technologies, Inc. (IDT), the global leader in nucleic acid synthesis, serving all areas of life sciences research and development, offers products for a broad range of genomics applications. IDT’s primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, next generation sequencing, synthetic biology, and functional genomics. With manufacturing facilities in the United States, Belgium, and Singapore, IDT synthesizes more than 55,000 custom oligonucleotides per day for over 85,000 customers worldwide. For more information, visit www.idtdna.com
and follow @idtdna
Media Contact (Caribou Biosciences, Inc.):
Feinstein Kean Healthcare
Contact (Integrated DNA Technologies, Inc.):
Manager, Corporate Communications and Sustainability
+1 (847) 745-1749